The Latest Cardiac and Vascular News
NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced that it has entered into a $20 million credit facility agreement with Silicon Valley Bank (SVB), the bank of the world’s most […]
Double-blind, randomized trial data demonstrates clinically meaningful and statistically significant difference of 8.1 mmHg in reduction of 24-hour ambulatory systolic blood pressure at 6 months vs. control High responder rate despite 88.5% of treated patients having isolated systolic hypertension (ISH) Primary safety endpoint achieved with no difference in major cardiac […]
First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease Follows Breakthrough Device designation for Virtue Sirolimus-Eluting Balloon in coronary in-stent restenosis granted in Q2 2019 NEW HOPE, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation […]
Late-breaking BackBeat CNT™ randomized, double-blind clinical results selected by Cardiovascular Research Foundation for presentation at TCT 2019 NEW HOPE, Pa., Sept. 04, 2019 (GLOBE NEWSWIRE) — Orchestra BioMed™, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, announced today […]
Dr. Donohoe brings nearly 30 years of successful clinical and regulatory experience advancing medical devices in the cardiology and endovascular space NEW HOPE, Pa., Aug. 27, 2019 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in […]
Series B-1 Round Led by Perceptive, RTW and Soleus Capital with Strategic Participation from Terumo Corporation Secures $64 Million in 2019 Capital Inflows, Including $30 Million Upfront Payment from Terumo Partnership Financing Structure Provides Up to an Additional $57 Million in Follow-On Investments from Existing Shareholders NEW HOPE, Pa., July […]
TOKYO, June 13, 2019 /PRNewswire/ — Terumo Corporation (TSE: 4543), a leading global medical device manufacturer, today announced that it has secured exclusive global development and commercialization rights to Virtue® Sirolimus-Eluting Balloon (SEB) for percutaneous coronary interventions by entering into a strategic partnership with Orchestra BioMed, Inc., a biomedical innovation company providing high-impact solutions […]
NEW HOPE, Pa., April 24, 2019 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet healthcare needs, announced today that it has secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its Virtue® Sirolimus-Eluting […]
NEW HOPE, Pa., Dec. 04, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief Financial Officer (CFO). Mr. Ballantyne is an experienced financial and […]
NEW HOPE, Pa., Nov. 20, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, today announced that David Hochman, Chairman and Chief Executive Officer, will present a corporate overview at the Piper Jaffray Healthcare […]
